ReviewCurrent oncology reports2012
RET TKI: potential role in thyroid cancers.
Review in Current oncology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The pyrazolo[3,4-d]pyrimidine derivative CLM24 has an antineoplastic effect in aggressive dedifferentiated thyroid cancer in vitro.Endocrine · 2026Article
- The value of preoperative molecular testing in the management of Bethesda V and Bethesda VI thyroid tumors.Hormones (Athens, Greece) · 2025Review
- Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.Cancer management and research · 2019Article
- Molecular testing in the diagnosis of differentiated thyroid carcinomas.Gland surgery · 2018Review
- Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration.Frontiers in endocrinology · 2018Article
- StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.Cancer medicine · 2017Article
- CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.Endocrine · 2016Article
- Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.Pathology oncology research : POR · 2015Article
- New therapies for dedifferentiated papillary thyroid cancer.International journal of molecular sciences · 2015Review
- Selective use of vandetanib in the treatment of thyroid cancer.Drug design, development and therapy · 2015Review
- Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.International journal of clinical and experimental pathology · 2015Article
- Advances in thyroid cancer treatment: latest evidence and clinical potential.Therapeutic advances in medical oncology · 2015Review
- Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules.Current genomics · 2014Article
- Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer science · 2013Article
- Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.International journal of endocrinology · 2013Article
- The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.Acta pharmacologica Sinica · 2012Article
- Vandetanib: in medullary thyroid cancer.Drugs · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET(sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.
Indexed as
Identifiers
22286373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.